ICE Bioscience Posters

Download

In drug discovery, proactive toxicological risk assessment of candidate compounds is crucial for avoiding clinical-stage failure and post-market withdrawal. However, traditional preclinical safety evaluation strategies have significant limitations: in vivo animal studies exhibit low human relevance (translatability) due to significant species differences and face dual pressures of ethics and cost; while conventional in vitro binding assays are inadequate for predicting functional biological effects. Notably, approximately 75% of clinical adverse drug reactions (ADRs) originate from dose-dependent off-target effects, highlighting an urgent need for more accurate early-risk identification tools. To address these challenges, the IQ DruSafe consortium—a preeminent alliance of global pharmaceutical companies—has championed the enhancement of preclinical predictive power through the expansion and refinement of secondary pharmacology screening strategies. This study is aligned with this initiative and aims to investigate the implementation of an advanced in vitro secondary pharmacology screening system utilizing functional assay formats. By generating richer pharmacological information beyond mere binding affinity, this strategy seeks to enable a more accurate and earlier identification of potential safety liabilities, thereby providing highly translatable safety insights for the optimization of lead compounds.